Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Viatris Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.25, while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc pays a 2.91% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Viatris Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $17.86 |
52-Week Low | $21.76 | $9.49 |
Market Cap | — | $18.95B |
Enterprise Value | — | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF has delivered 12.66% year-to-date returns through June 8, 2026, outperforming the S&P 500. Recent stock splits on June 25-26, 2026, adjusted the share structure.
The leveraged ETF offers amplified exposure to Nvidia's AI-driven growth but faces risks from daily reset mechanics and tracking divergence. With Nvidia continuing to beat earnings estimates and maintain AI leadership, NVDL provides tactical upside potential, though volatility compression and leverage decay remain significant concerns for long-term holders.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
